餐後右上腹痛 (4粒試用裝) | Right Upper Abdominal Pain After Meal (Trial 4 Capsules)

SKU 00008b
HK$0.00
In stock
1
Product Details

醇脂膽酸 研究資料

如你有此疾病,請遵照閣下醫生的完整醫療方案;而是否使用多學科復康方案前,你必須咨詢主診醫生的意見,如果閣下的主診醫生不建議您加入補充劑調理組合,請你不要使用。如果你需要尋求其他醫生作第二咨詢,閣下可聯絡我們線上<無邊界醫生>。或你自己城市內的其他專業醫生的再診斷。

<<此優惠只接受線上下單,快遞費港幣36元>>


非酒精性脂肪肝

  • 非酒精性脂肪性肝病(NAFLD)是由肝臟脂肪堆積引起的一系列疾病的術語。這通常見於超重或肥胖的人。
  • 健康的肝臟應該含有很少或沒有脂肪。據估計,在英國,每3個人中就有1人患有NAFLD早期,肝臟中含有少量脂肪。
  • 早期NAFLD通常不會造成任何傷害,但如果病情惡化,可能會導致嚴重的肝臟損害,包括肝硬化。
  • 肝臟脂肪含量高也會新增患嚴重健康問題的風險,如糖尿病、高血壓和腎病。
  • 如果你已經患有糖尿病,NAFLD會新增你患心臟病的幾率。如果在早期發現並處理,就有可能封锁NAFLD惡化,减少肝臟中的脂肪量。(1)

NAFLD的主要階段是:

  1. 單純性脂肪肝(脂肪變性)——肝細胞中的一種基本無害的脂肪堆積,只有在出於其他原因進行的檢測中才能診斷出來
  2. 非酒精性脂肪性肝炎(NASH)——一種更嚴重的NAFLD,肝臟發炎;據估計,這將影響多達5%的英國人口
  3. 纖維化——持續的炎症導致肝臟周圍和附近血管的疤痕組織,但肝臟仍能正常工作
  4. 肝硬化——最嚴重的階段,發生在多年炎症後,肝臟萎縮,結疤和結塊;這種損傷是永久性的,可能導致肝衰竭(肝臟停止正常工作)和肝癌

纖維化或肝硬化的發展可能需要數年時間。改變生活方式以防止病情惡化是很重要的。

我是否有患非酒精性脂肪肝(NAFLD)的風險?

如果您:

  • 肥胖或超重——特別是如果你腰間有很多脂肪(蘋果形的體型)
  • 患有2型糖尿病
  • 高血壓
  • 高膽固醇
  • 患有代謝綜合征(糖尿病、高血壓和肥胖的綜合征)
  • 他們都超過50歲了
  • 吸烟

但NAFLD的診斷對象是沒有任何這些危險因素的人,包括幼兒。

雖然與酒精相關肝病(ARLD)非常相似,但NAFLD並不是由飲酒過量引起的。

非酒精性脂肪肝(NAFLD)的症狀

NAFLD早期通常沒有任何症狀。除非在出於其他原因進行的測試中被診斷出來,否則你可能不會知道自己患有此病。

偶爾,非酒精性脂肪性肝炎或纖維化(NAFLD的更晚期)患者可能會經歷:

  • 腹部右上方(肋骨右下方)隱隱或疼痛
  • 極度疲勞
  • 不明原因的體重減輕
  • 乏力

如果肝硬化(最晚期)發展,你可能會出現更嚴重的症狀,如:

  • 皮膚和眼白變黃(黃疸)、
  • 皮膚瘙癢、
  • 腿部、脚踝、脚部或腹部腫脹(水腫)。

重點研究成果:

  • 降低肝臟脂質水准: 已經證明肝臟脂質代謝的內穩態破壞最可能是FLD早期的原因,牛磺酸通過降低甘油三酯(TG)和膽固醇水准在減輕肝臟脂肪變性中發揮作用(2)
  • 非酒精性脂肪肝: 膽汁酸訊號與生物失調和非酒精性脂肪肝密切相關。在過去的十年中,在動物模型和臨床試驗中,用其激動劑刺激膽汁酸受體已被廣泛用於治療非酒精性脂肪肝。早期證據表明膽汁酸受體激動劑在非酒精性脂肪肝治療中的潜力,但其長期安全性和有效性需要進一步澄清。(3)
  • 膽管炎: 一項多中心、隨機、雙盲試驗,比較TUDCA和UDCA對中國原發性膽管炎患者的療效和安全性(4)
  • 肝酶及血脂: 血清肝酶水平显著降低(P<0.001)相关。天冬氨酸转氨酶、丙氨酸转氨酶和γ-谷氨酰转氨酶水平平均下降29.7%± 14.5%, 24.1 ± 15.9%和26.6%± 治疗1个月后分别为19.9%,治疗3个月后增加5%~10%。总胆红素水平也略有改善。(9)
  • 肝硬化: 治疗肝硬化是安全有效的,尤其在改善生化表达方面优于UDCA。然而,两种药物在6个月的治疗中对肝纤维化的血清标志物没有影响。(5)
  • 膽息肉: 12例患者均檢出病變:8例為單發、固著性病變;2例有多發性、固著性病變;2例有多發性有蒂病變。病變大小從4毫米到18毫米不等。12例中8例6個月後息肉完全消失,1例3個月後息肉完全消失。無論息肉的大小和部位如何,息肉都會溶解。(6)
  • 高胆固醇: 高胆固醇血症发生在64%的胆石症患者和56%的胆囊胆固醇病患者中。68%的胆石症患者和69%的胆囊胆固醇病患者的总胆固醇水平缓慢升高(在5.3-6.1 mmol/l范围内),高胆固醇血症很少发生,且不超过2-4%。在45%的胆石症患者和49%的胆囊胆固醇病患者中,熊果糖治疗3个月后高胆固醇血症消失。(7)
  • 膽紅素鈣結石: 膽紅素鈣結石的溶解和崩解目的探討人膽汁中溶石劑的作用及對犬膽管沖洗的影響。(10)
  • 銀屑病: 匈牙利的研究:銀屑病口服膽汁酸補充1至6周,加上飲食中富含蔬菜和水果,不含熱香料、酒精、生洋葱、大蒜和碳酸軟飲料,78.8%的患者症狀得到緩解,而接受常規治療的患者中只有24.9%在治療期間痊癒。膽酸效應在急性型銀屑病中更為明顯;95.1%的患者無症狀。2年後無症狀者占57.9%,而常規治療為6.0%。(8)


多學科研證復康方案

  • 藥物及其他醫療方案,請遵醫從醫生建議
  • 飲食營養請依營養師指引
  • 運動及或心理輔導,請參考各專家建議

產品名稱: 醇脂膽酸 / CHOLIPOLYSIS CHOLIC ACID

規格: 300毫克/胃溶膠囊/4粒/袋裝

份量: 4粒(每粒300毫克)/袋

建議用法:食用1至3粒,每日2-3次,於午餐及晚餐時食用。

注意事項: 小童、孕婦或哺乳期,請勿使用。

儲存: 請存放於陰涼乾爽處,避免陽光照射。

產地: 中國香港

重點關注:

  • 追縱肝脂代謝
  • 監視非酒脂
  • 關注肝酶水平
  • 瞄準膽管健康
  • 憎恨膽息肉
  • 重視胆固醇

注意:

  • 本品為營養補充品,不能代替藥物
  • 如有不適反應,建議停止服用
  • 妊娠期和哺乳期婦女不能食用
  • 如不瞭解問題原因或問題持續,請儘快諮詢醫生
  • 有身體過敏,不要食用本品。

主要成份

Major Ingredients

胆酸二水合物

Taurolite

胆汁酸

Bile Acid

3α,7β二羟基胆烷酰-N-牛磺酸

3α,7β-dihydroxy-5β-cholanoyl Taurine

牛磺熊去氧胆酸

Tauroursodeoxycholic Acid

牛磺酸

Taurine

胡椒提取物

Pepper Extracts


CHOLIPOLYSIS CHOLIC ACID
If you have this disease, please follow your doctor's complete medical plan; Before using the multidisciplinary rehabilitation program, you must consult the attending doctor. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek a second consultation from another doctor, you can contact our online doctor without borders. Or another professional doctor in your own city.

<>

Nonalcoholic fatty liver
Nonalcoholic fatty liver disease (NAFLD) is a term for a series of diseases caused by liver fat accumulation. This is usually seen in overweight or obese people.
A healthy liver should contain little or no fat. It is estimated that one in three people in the UK has NAFLD in the early stage, and the liver contains a small amount of fat.
Early NAFLD usually does not cause any harm, but if the condition worsens, it may lead to serious liver damage, including cirrhosis.
High levels of liver fat also increase the risk of serious health problems, such as diabetes, hypertension and kidney disease.
If you already have diabetes, NAFLD wll increase your chances of heart disease. If detected and treated early, it is possible to block the deterioration of NAFLD and reduce the amount of fat in the liver. (1)
The main phases of NAFLD are:
  1. Simple fatty liver (steatosis) - a basically harmless accumulation of fat in hepatocytes that can only be diagnosed by testing for other reasons
  2. Nonalcoholic steatohepatitis (NASH) - a more severe NAFLD with inflammation of the liver; It is estimated that this will affect up to 5% of the UK population
  3. Fibrosis - persistent inflammation leads to scar tissue around and near the liver, but the liver still works normally
  4. Cirrhosis - the most severe stage, occurs after years of inflammation, liver atrophy, scarring and caking; This damage is permanent and can lead to liver failure (the liver stops working normally) and liver cancer
  5. The development of fibrosis or cirrhosis may take years. It is important to change your lifestyle to prevent the disease from getting worse.
Do I have the risk of nonalcoholic fatty liver disease (NAFLD)?
If you:
  • Obese or overweight - especially if you have a lot of fat around your waist (apple shaped body)
  • Type 2 diabetes mellitus
  • high blood pressure
  • High cholesterol
  • Metabolic syndrome (diabetes, hypertension and obesity syndrome)
  • They are all over 50
  • smoke
However, NAFLD is diagnosed in people without any of these risk factors, including young children.
Although very similar to alcohol-related liver disease (arld), NAFLD is not caused by excessive drinking.
Symptoms of nonalcoholic fatty liver disease (NAFLD)
NAFLD usually has no symptoms in the early stage. You may not know you have the disease unless you are diagnosed in a test for other reasons.
Occasionally, patients with nonalcoholic steatohepatitis or fibrosis (more advanced stage of NAFLD) may experience:
  • Faint or pain in the upper right of the abdomen (lower right of the ribs)
  • Extreme fatigue
  • Unexplained weight loss
  • weakness
If cirrhosis (the most advanced stage) develops, you may develop more serious symptoms, such as:
  • Yellowing of skin and eyes (jaundice)
  • Skin itching
  • Swelling (edema) in the legs, ankles, feet or abdomen.
Key research results:
  • Reducing liver lipid level: it has been proved that the destruction of liver lipid metabolism is the most likely cause of early FLD. Taurine plays a role in reducing liver steatosis by reducing triglyceride (TG) and cholesterol levels (2)
  • Nonalcoholic fatty liver: bile acid signal is closely related to biological disorders and nonalcoholic fatty liver. In the past decade, stimulating bile acid receptors with its agonists has been widely used in the treatment of nonalcoholic fatty liver in animal models and clinical trials. Early evidence indicates the potential of bile acid receptor agonists in the treatment of nonalcoholic fatty liver, but its long-term safety and efficacy need to be further clarified. (3)
  • Cholangitis: a multicenter, randomized, double-blind trial to compare the efficacy and safety of TUDCA and UDCA in Chinese patients with primary cholangitis (4)
  • Liver enzyme and blood lipid: the level of serum liver enzyme decreased significantly (P < 0.001). Aspartate aminotransferase, alanine aminotransferase and γ- The average level of glutamyl aminotransferase decreased by 29.7% ± 14.5%, 24.1 ± 15.9% and 26.6% ± 19.9% after one month of treatment, and increased by 5% ~ 10% after three months of treatment. The level of total bilirubin also improved slightly. (9)
  • Liver cirrhosis: the treatment of liver cirrhosis is safe and effective, especially better than UDCA in improving biochemical expression. However, both drugs had no effect on serum markers of liver fibrosis at 6 months of treatment. (5)
  • Biliary polyps: lesions were detected in 12 patients: 8 cases were single and fixed lesions; 2 cases had multiple and fixed lesions; 2 cases had multiple pedicled lesions. The lesion size ranged from 4 mm to 18 mm. Of the 12 cases, the polyps disappeared completely in 8 cases after 6 months and in 1 case after 3 months. Polyps dissolve regardless of their size and location. (6)
  • Hypercholesterolemia: Hypercholesterolemia occurs in 64% of patients with cholelithiasis and 56% of patients with gallbladder cholesterol disease. 68% of patients with cholelithiasis and 69% of patients with gallbladder cholesterol disease have a slow increase in total cholesterol levels (in the range of 5.3-6.1 mmol / L), and hypercholesterolemia rarely occurs, and does not exceed 2-4%. In 45% of patients with cholelithiasis and 49% of patients with gallbladder cholesterol disease, hypercholesterolemia disappeared after 3 months of ursulose treatment. (7)
  • Calcium bilirubin stone: dissolution and disintegration of calcium bilirubin stone objective to investigate the effect of stone dissolving agent in human bile and its effect on bile duct irrigation in dogs. (10)
  • Psoriasis: Hungarian study: oral bile acid supplementation for psoriasis for 1 to 6 weeks, coupled with a diet rich in vegetables and fruits, free of hot spices, alcohol, raw onions, garlic and carbonated soft drinks, 78.8% of patients' symptoms were relieved, while only 24.9% of patients receiving routine treatment recovered during treatment. Cholic acid effect is more obvious in acute psoriasis; 95.1% of the patients were asymptomatic. After 2 years, 57.9% were asymptomatic, while 6.0% were treated with routine treatment. (8)

Product Name: CHOLIPOLYSIS CHOLIC ACID
Specification: 300 mg / stomach soluble capsule / 4 capsules / bag
Serving size: 4 Capsules (300 mg / capsule) / bag
Recommended usage: Take 1 to 3 capsules, 2-3 times a day, at lunch and dinner.
Precautions: children, pregnant women or lactation, do not use.
Storage: Please store in a cool and dry place to avoid sunlight.
Origin: Hong Kong, China
Focus on:
  • Chase vertical Hepatic lipid metabolism
  • Monitoring non alcoholic fat
  • Pay attention to liver enzyme level
  • Targeting bile duct health
  • Hate Biliary polyp
  • Pay attention to cholesterol


Refs參考文獻:

  1. https://www.nhs.uk/conditions/non-alcoholic-fatty-...
  2. Tang R. et al. (2019) Preventive or Curative Administration of Taurine Regulates Lipid Metabolism in the Liver of Rats with Alcoholic Liver Disease. In: Hu J., Piao F., Schaffer S., El Idrissi A., Wu JY. (eds) Taurine 11. Advances in Experimental Medicine and Biology, vol 1155. Springer, Singapore. https://doi.org/10.1007/978-981-13-8023-5_11
  3. Caihua Wang,1 Chunpeng Zhu,1 Liming Shao,1 Jun Ye,1 Yimin Shen,2 and Yuezhong Ren. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Volume 2019 |Article ID 7659509 | https://doi.org/10.1155/2019/7659509
  4. Hong Ma, Minde Zeng, Ying Han, Huiping Yan. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. November 2016. Medicine 95(47):e5391. DOI:10.1097/MD.0000000000005391
  5. Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):189-194. doi: 10.1007/s11596-013-1095-x. Epub 2013 Apr 17. PMID: 23592128.
  6. G. Del Favero, F. Di Mario, T. Meggiato, P. Scalon, F.A. Bulzacchi, F. Mangano, G. Ricciardi, F. Battocchio, A. Caroli, Disappearance of gallbladder wall lesions after oral bile acids treatment—A pilot study, Current Therapeutic Research, Volume 54, Issue 4, 1993, Pages 384-388, ISSN 0011-393X, https://doi.org/10.1016/S0011-393X(05)80640-X.
  7. Il'chenko AA, Drozhzhina IuV. [Effect of ursodeoxycholic acid on the characteristics of lipid metabolism in cholelithiasis and gall-bladder cholesterosis]. Eksp Klin Gastroenterol. 2007;(5):29-34, 164. Russian. PMID: 18389594.
  8. Joseph E. Pizzorno, Michael T. Murray, Herb Joiner-Bey,69 - Psoriasis,
  9. Mario Angelico, Costanzo Del Vecchio, Alessandro Nistri,Effect of tauroursodeoxycholic acid on serum liver enzyme and serum lipid levels in patients with chronic active hepatitis,Current Therapeutic Research,Volume 56, Issue 6,1995,Pages 626-634,ISSN 0011-393X,https://doi.org/10.1016/0011-393X(95)85055-4.
  10. YOSHIHIRO TAKASAWA, NORIYOSHI SUZUKI, WATARU TAKAHASHI and TOSHIO SATO. A Study on the Dissolution and Disintegration of Calcium Bilirubinate Stones, with Special Reference to Effects of Litholytic Agents in Human Bile and to Irrigation of Bile Duct in Dogs. Tohoku J. exp. Med., 1982, 138, 383-395.
  11. Editor(s): Joseph E. Pizzorno, Michael T. Murray, Herb Joiner-Bey,The Clinician's Handbook of Natural Medicine (Third Edition),Churchill Livingstone,2016,Pages 864-874,ISBN 9780702055140 https://doi.org/10.1016/B978-0-7020-5514-0.00078-6.
Save this product for later